A new #SciencePerspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes and obesity, including cardiovascular disease and neurodegenerative disorders.
Teacher, Clinical Supervisor
Clinical Associate Professor, Psychiatry
University of Florida
Affiliation is for identification only. All content and opinions are my own.
View more posts
Gator Psychiatry 